Biora Therapeutics, Inc.
Biora Therapeutics, Inc.
Your view on BIORQ
Overview
What the company does, where it operates, and who runs it.
About Biora Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Aditya Mohanty
- Headquarters
- 4330 La Jolla Village Drive, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Aditya Mohanty
- Headquarters
- 4330 La Jolla Village Drive, San Diego, CA, US
Biora Therapeutics, Inc. operates as a biotechnology company, primarily focused on developing innovative oral biotherapeutics. The company's core efforts include: 1.
Targeted Therapeutics Program: This initiative employs an advanced, ingestible smart capsule engineered for the precise administration of medications directly within the gastrointestinal (GI) tract. The aim is to enhance the efficacy of treatments for inflammatory bowel diseases. 2.
Systemic Therapeutics Program: Utilizing an orally delivered capsule, this program offers a non-invasive method for delivering biotherapeutics. These are released straight into the intestinal mucosa, facilitating improved absorption into the bloodstream and broader systemic effects, thereby eliminating the need for injections.
Additionally, Biora Therapeutics is engaged in creating diagnostic devices. These tools are designed to evaluate the characteristics of the GI tract and identify various digestive conditions, such as small intestine bacterial overgrowth (SIBO), by enabling diagnosis directly where the disease manifests.
Established in 2010, the company previously operated under the name Progenity, Inc. It rebranded as Biora Therapeutics, Inc. in April 2022 to underscore its strategic focus on its therapeutic product pipeline. Its headquarters are situated in San Diego, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Biora Therapeutics, Inc., and the rating behind it. BIORQ last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Biora Therapeutics, Inc.. Starting points for Biora Therapeutics, Inc.: EPS -$78.69, beta 5.31 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Biora Therapeutics, Inc.. Biora Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Biora Therapeutics, Inc.. Trailing twelve-month EPS for Biora Therapeutics, Inc. stands at -$78.69. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Biora Therapeutics, Inc.. Biora Therapeutics, Inc. has reported as a listed company since 2025. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Biora Therapeutics, Inc. valued side by side against its closest peers. Biora Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Biora Therapeutics, Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Biora Therapeutics, Inc. executives and directors. Shares of Biora Therapeutics, Inc. have traded between $0.0000 and $0.0050 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Biora Therapeutics, Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Biora Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Biora Therapeutics, Inc.. Coverage tracks Biora Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.